ScanStation - Faster, Automated Plate Counting for Industry

Trillium Diagnostics Sold to Vivione Biosciences

Vivione Biosciences Inc. is to acquire all of the capital stock of Trillium Diagnostics for US$1.5 million in cash and US$4 million in common shares of Vivione at closing along with subsequent milestone-related.

Trillium is involved in the emerging area of immune-profiling that brings the approach of personalized medicine to infectious disease and sepsis diagnostics.Trillium's lead product, Leuko64, is a quantitative test for neutrophil CD64 expression, a marker directly associated with sepsis diagnosis.


     
Tags: Sepsis

Date Published: February 3, 2015

Source article link: Vivione Biosciences » company contact details
Join us on Google+

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed